Scientific Statement

Health Policy

May 09, 2022

Endocrine Health and Health Care Disparities in the Pediatric and Sexual and Gender Minority Populations

May 2023/JCEM: This scientific statement expands the Society’s 2012 statement by focusing on endocrine disease disparities in the pediatric population and sexual and gender minority populations. Read the Statement.

Adverse Health Consequences of Performance-Enhancing Drugs

June 2014/Endocrine Reviews: Despite the high prevalence of performance-enhancing drug (PED) use, media attention has focused almost entirely on PED use by elite athletes to illicitly gain a competitive advantage in sports, and not on the health risks of PEDs. Read the Statement.

Compounded Bioidentical Hormones in Endocrinology Practice

April 2016/JCEM: Custom-compounded bioidentical hormone therapy (HT) has become widely used in current endocrine practice, which has led to unnecessary risks with treatment. Read the Statement.

Health Disparities in Endocrine Disorders: Biological, Clinical, and Nonclinical Factors

September 2012/JCEM: Several themes emerged in the statement, including a need for basic science, population-based, translational and health services studies to explore underlying mechanisms contributing to endocrine health disparities. Read the Statement.

Last Updated:
Back to top

Who We Are

For 100 years, the Endocrine Society has been at the forefront of hormone science and public health. Read about our history and how we continue to serve the endocrine community.